Faruqi & Faruqi Investigates Potential Claims Against Atara Biotherapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ATRA?
Source: PRnewswire
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. for the period between May 20, 2024, and January 9, 2026, indicating possible legal risks that could undermine investor confidence.
- Investor Rights Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, necessitating prompt action from investors to protect their rights, which may impact the company's stock performance.
- Direct Contact Encouragement: Partner Josh Wilson encourages investors who purchased Atara securities during the specified period to contact him directly for legal consultation, demonstrating the firm's commitment to supporting its clients.
- Potential Litigation Impact: Should the investigation substantiate claims, Atara may face significant financial liabilities, potentially affecting its market performance and investor confidence, highlighting the legal risks that could threaten the company's operations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.170
Low
18.00
Averages
21.50
High
25.00
Current: 5.170
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates Potential Claims Against Atara Biotherapeutics
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. for the period between May 20, 2024, and January 9, 2026, indicating possible legal risks that could undermine investor confidence.
- Investor Rights Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, necessitating prompt action from investors to protect their rights, which may impact the company's stock performance.
- Direct Contact Encouragement: Partner Josh Wilson encourages investors who purchased Atara securities during the specified period to contact him directly for legal consultation, demonstrating the firm's commitment to supporting its clients.
- Potential Litigation Impact: Should the investigation substantiate claims, Atara may face significant financial liabilities, potentially affecting its market performance and investor confidence, highlighting the legal risks that could threaten the company's operations.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, alleging the company misled investors regarding its drug candidate's manufacturing issues.
- Regulatory Scrutiny Risks: The complaint highlights that deficiencies in the ALLELE study make FDA approval of tabelecleucel's Biologics License Application (BLA) unlikely, which not only jeopardizes the company's regulatory prospects but also poses significant risks to ongoing clinical trials and overall financial health.
- Stock Price Plunge: Following a press release on January 12, 2026, announcing another Complete Response Letter (CRL) from the FDA regarding tabelecleucel, Atara's stock price fell by $7.79, or 56.99%, closing at $5.88 per share, reflecting market pessimism about the company's future.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by May 22, 2026, emphasizing the importance of corporate governance and executive accountability, with all representation on a contingency fee basis, requiring no upfront payment.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics in the Central District of California on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws, indicating significant investor concerns about the company's future prospects.
- FDA Regulatory Risks: Atara's Biologics License Application for tabelecleucel received a Complete Response Letter (CRL) from the FDA, citing good manufacturing practice (GMP) compliance issues at a third-party facility, which heightens regulatory scrutiny and jeopardizes ongoing clinical trials, potentially delaying product approval.
- Stock Price Volatility: Following the CRL announcement on January 16, 2025, Atara's stock plummeted by 40.5% to $7.83 per share, reflecting a severe lack of market confidence in the company's regulatory compliance capabilities and exacerbating investor anxiety.
- Deteriorating Financial Condition: With the FDA placing a clinical hold on tabelecleucel trials, Atara's stock fell by 56.99% to $5.88 per share on January 12, 2026, highlighting increasing financial pressures that may hinder future funding and operational capabilities.
See More
Class Action Lawsuit Announced for Atara Biotherapeutics
- Class Action Initiation: Rosen Law Firm announces a class action lawsuit on behalf of Atara Biotherapeutics (NASDAQ: ATRA) securities purchasers from May 20, 2024, to January 9, 2026, indicating potential investor losses due to misleading statements.
- Compensation Structure: Participants may receive compensation through a contingency fee arrangement without upfront costs, reducing financial barriers for affected investors and encouraging broader participation in the lawsuit.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and expertise in handling similar cases.
- Case Details Unveiled: The lawsuit alleges that Atara failed to disclose manufacturing issues and clinical trial risks during the class period, leading to investor misunderstandings about its financial health, which could significantly impact the company's future market performance.
See More
Multiple Companies Face Class Action Lawsuit Reminder
- Atara Biotherapeutics Lawsuit: A class action lawsuit against Atara Biotherapeutics, Inc. alleges that from May 20, 2024, to January 9, 2026, the company failed to disclose critical facts regarding its manufacturing and tabelecleucel's regulatory prospects, leading to significant investor losses, with a deadline of May 22, 2026, to apply as lead plaintiff.
- Coty's Fragrance Segment Issues: Coty Inc. is facing a class action lawsuit alleging that between November 5, 2025, and February 4, 2026, it failed to disclose material facts about slowing growth in its Prestige fragrance segment, prompting affected investors to seek lead plaintiff status by May 22, 2026.
- Vital Farms ERP Implementation Dispute: The class action lawsuit against Vital Farms, Inc. claims that from May 8, 2025, to February 26, 2026, the company did not disclose important facts regarding the implementation of its new enterprise resource planning system, with a lead plaintiff application deadline of May 26, 2026.
- Super Micro Compliance Issues: Super Micro Computer, Inc. is involved in a class action lawsuit alleging non-compliance with export control laws from April 30, 2024, to March 19, 2026, with investors needing to apply for lead plaintiff status by May 26, 2026, if they suffered losses during this period.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Atara Biotherapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 20, 2024, and January 9, 2026, with a deadline to contact the firm by May 22, 2026, to participate.
- False Statements Allegation: The complaint alleges that Atara faced manufacturing issues and deficiencies in its ALLELE study, making FDA approval of its BLA for tabelecleucel unlikely, while the company overstated the drug's prospects, leading to investor losses.
- Increased Regulatory Risk: Atara's manufacturing defects have heightened the risk of regulatory action, rendering its public statements false and materially misleading, which further undermines investor confidence and impacts the company's stock price.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations, encouraging affected investors to reach out to discuss their rights, showcasing the firm's expertise in representing investors in securities class action lawsuits globally.
See More
Faruqi & Faruqi Investigates Potential Claims Against Atara Biotherapeutics
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. for the period between May 20, 2024, and January 9, 2026, indicating possible legal risks that could undermine investor confidence.
- Investor Rights Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, necessitating prompt action from investors to protect their rights, which may impact the company's stock performance.
- Direct Contact Encouragement: Partner Josh Wilson encourages investors who purchased Atara securities during the specified period to contact him directly for legal consultation, demonstrating the firm's commitment to supporting its clients.
- Potential Litigation Impact: Should the investigation substantiate claims, Atara may face significant financial liabilities, potentially affecting its market performance and investor confidence, highlighting the legal risks that could threaten the company's operations.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, alleging the company misled investors regarding its drug candidate's manufacturing issues.
- Regulatory Scrutiny Risks: The complaint highlights that deficiencies in the ALLELE study make FDA approval of tabelecleucel's Biologics License Application (BLA) unlikely, which not only jeopardizes the company's regulatory prospects but also poses significant risks to ongoing clinical trials and overall financial health.
- Stock Price Plunge: Following a press release on January 12, 2026, announcing another Complete Response Letter (CRL) from the FDA regarding tabelecleucel, Atara's stock price fell by $7.79, or 56.99%, closing at $5.88 per share, reflecting market pessimism about the company's future.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by May 22, 2026, emphasizing the importance of corporate governance and executive accountability, with all representation on a contingency fee basis, requiring no upfront payment.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics in the Central District of California on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws, indicating significant investor concerns about the company's future prospects.
- FDA Regulatory Risks: Atara's Biologics License Application for tabelecleucel received a Complete Response Letter (CRL) from the FDA, citing good manufacturing practice (GMP) compliance issues at a third-party facility, which heightens regulatory scrutiny and jeopardizes ongoing clinical trials, potentially delaying product approval.
- Stock Price Volatility: Following the CRL announcement on January 16, 2025, Atara's stock plummeted by 40.5% to $7.83 per share, reflecting a severe lack of market confidence in the company's regulatory compliance capabilities and exacerbating investor anxiety.
- Deteriorating Financial Condition: With the FDA placing a clinical hold on tabelecleucel trials, Atara's stock fell by 56.99% to $5.88 per share on January 12, 2026, highlighting increasing financial pressures that may hinder future funding and operational capabilities.
See More
Class Action Lawsuit Announced for Atara Biotherapeutics
- Class Action Initiation: Rosen Law Firm announces a class action lawsuit on behalf of Atara Biotherapeutics (NASDAQ: ATRA) securities purchasers from May 20, 2024, to January 9, 2026, indicating potential investor losses due to misleading statements.
- Compensation Structure: Participants may receive compensation through a contingency fee arrangement without upfront costs, reducing financial barriers for affected investors and encouraging broader participation in the lawsuit.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and expertise in handling similar cases.
- Case Details Unveiled: The lawsuit alleges that Atara failed to disclose manufacturing issues and clinical trial risks during the class period, leading to investor misunderstandings about its financial health, which could significantly impact the company's future market performance.
See More
Multiple Companies Face Class Action Lawsuit Reminder
- Atara Biotherapeutics Lawsuit: A class action lawsuit against Atara Biotherapeutics, Inc. alleges that from May 20, 2024, to January 9, 2026, the company failed to disclose critical facts regarding its manufacturing and tabelecleucel's regulatory prospects, leading to significant investor losses, with a deadline of May 22, 2026, to apply as lead plaintiff.
- Coty's Fragrance Segment Issues: Coty Inc. is facing a class action lawsuit alleging that between November 5, 2025, and February 4, 2026, it failed to disclose material facts about slowing growth in its Prestige fragrance segment, prompting affected investors to seek lead plaintiff status by May 22, 2026.
- Vital Farms ERP Implementation Dispute: The class action lawsuit against Vital Farms, Inc. claims that from May 8, 2025, to February 26, 2026, the company did not disclose important facts regarding the implementation of its new enterprise resource planning system, with a lead plaintiff application deadline of May 26, 2026.
- Super Micro Compliance Issues: Super Micro Computer, Inc. is involved in a class action lawsuit alleging non-compliance with export control laws from April 30, 2024, to March 19, 2026, with investors needing to apply for lead plaintiff status by May 26, 2026, if they suffered losses during this period.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Atara Biotherapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 20, 2024, and January 9, 2026, with a deadline to contact the firm by May 22, 2026, to participate.
- False Statements Allegation: The complaint alleges that Atara faced manufacturing issues and deficiencies in its ALLELE study, making FDA approval of its BLA for tabelecleucel unlikely, while the company overstated the drug's prospects, leading to investor losses.
- Increased Regulatory Risk: Atara's manufacturing defects have heightened the risk of regulatory action, rendering its public statements false and materially misleading, which further undermines investor confidence and impacts the company's stock price.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations, encouraging affected investors to reach out to discuss their rights, showcasing the firm's expertise in representing investors in securities class action lawsuits globally.
See More
